Catégorie : Essais Cliniques

Troubles anxieux : le CBD peut soulager les symptômes, Kalapa Clinic, 30/06/2020

Troubles anxieux : le CBD peut soulager les symptômes Kalapa Clinic, Barcelone, Espagne By Gesa|30/06/2020   La peur est une réaction naturelle à certaines situations et à certains événements. Elle remplit à la fois une fonction d’avertissement et de protection. Lors d’un trouble anxieux, cependant, elle développe une dynamique propre qui est très stressante pour les personnes concernées. Diverses études et rapports d’expérience indiquent que le cannabinoïde non-psychoactif cannabidiol (CBD) peut soulager leurs symptômes. En Allemagne, le trouble anxieux est la maladie mentale la plus courante, devançant même la dépression. Environ 12 millions de personnes sont touchées, les femmes plus souvent que les hommes (1). Le [...]

Lire la suite

Mind Menders: The Future of Psychedelics for Mental Illness, Batya Swift Yasgur, Medscape.com, 2020

Mind Menders: The Future of Psychedelics for Mental Illness Batya Swift Yasgur MA, LSW Medscape.com, November 10, 2020 https://www.medscape.com/viewarticle/940749?nlid=138288_425&src=WNL_mdplsfeat_201117_mscpedit_psyc&uac=292598PZ&spon=12&impID=2682236&faf=1   After a 50-year hiatus, psychedelic drugs are undergoing a research renaissance. Agents including psilocybin, methylenedioxymethamphetamine (MDMA), and others are all under investigation to treat a variety of psychiatric illnesses. Medscape spoke with Roland R. Griffiths, professor in the Departments of Psychiatry and Neuroscience and the Oliver Lee McCabe III Professor in the Neuropsychopharmacology of Consciousness, and director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University, Baltimore, Maryland, to discuss the status of these drugs in the United States and their therapeutic potential. Griffiths: Classic psychedelics are [...]

Lire la suite

The experimental effects of psilocybin on symptoms of anxiety and depression : A meta-analysis, Simon B. Goldberg et al, 2020

The experimental effects of psilocybin on symptoms of anxiety and depression : A meta-analysis Simon B. Goldberg, Brian T. Pace, Christopher R. Nicholas, Charles L. Raison, Paul R. Hutson Psychiatry Research, 2020, 284,  112749 Doi : 10.1016/j.psychres.2020.112749   A B S T R A C T The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges’ gs=1.16 to 1.47) and statistically significant. Across three placebo-controlled studies, pre-post placebo-controlled effects were also [...]

Lire la suite

Post-acute psychological effects of classical serotonergic psychedelics : a systematic review and meta-analysis, Simon B. Goldberg et al, 2020,

Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis Simon B. Goldberg, Benjamin Shechet, Christopher R. Nicholas, Chi Wing Ng, Geetanjali Deole, Zhuofan Chen and Charles L. Raison Psychological Medicine, 2020, 1–12. doi : 10.1017/S003329172000389X   Abstract Background. Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period; (2) test moderators of these effects; and (3) evaluate [...]

Lire la suite

Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand, Graham Gulbransen et al, 2020

Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand Graham Gulbransen, MBChB, FAChAM, FRNZCGP1*, William Xu2, Bruce Arroll, MBChB, PhD, FRNZCG BJGP Open, 2020, 1-8 DOI : 10.3399/bjgpopen20X101010   Abstract Background : Cannabidiol (CBD) is the non- euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear. Aim : To review the changes in self- reported quality of life measurements, drug tolerability, and dose- dependent relationships in patients prescribed CBD oil for various conditions at a single institution. Design & setting : An [...]

Lire la suite

Development of Ketamine Administration as a Treatment for Chronic PTSD, Abigail B. Collins et al., 2020

Development of Ketamine Administration as a Treatment for Chronic PTSD Abigail B. Collins, BS; Sarah B. Rutter, MA; and Adriana Feder, MD Psychiatric Annals, 2020, 50, (2), 68-76. doi : 10.3928/00485713-20200109-01   ABSTRACT Posttraumatic stress disorder (PTSD) is a highly prevalent, chronic, and dis-abling condition for which currently available pharmacotherapies are insuf-ficiently effective. Ketamine, which is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising and rapid-act-ing novel treatment intervention for this disorder. Findings from a proof-of-concept, randomized, controlled cross-over study of single-dose intravenous ketamine administration (compared to single-dose midazolam) in patients with chronic PTSD suggest that ketamine is associated with rapid improvement in [...]

Lire la suite

Psilocybin Delivers ‘Remarkable’ Relief in Severe Depression, Batya Swift Yasgur, 2020

Psilocybin Delivers 'Remarkable' Relief in Severe Depression Batya Swift Yasgur, MA, LSW Medscape.com, November 05, 2020   Psilocybin, the psychedelic compound in "magic mushrooms," rapidly improves symptoms and produces remission in as little as two sessions for patients with major depression, new research suggests. Results of a small randomized trial showed that treatment with psilocybin was associated with a greater than 50% reduction in depressive symptoms in 67% of study participants. In addition, 71% showed improvement at 4-week follow-up, with more than 50% achieving remission. "The finding that the majority of people whom we treated showed efficacy was quite a remarkable and gratifying finding and really sets the [...]

Lire la suite

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial, Alan K. Davis et al., 2020

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial Alan K. Davis, PhD; Frederick S. Barrett, PhD; Darrick G. May, MD; Mary P. Cosimano, MSW; Nathan D. Sepeda, BS; Matthew W. Johnson, PhD; Patrick H. Finan, PhD; Roland R. Griffiths, PhD JAMA Psychiatry, 2020, E1-E9. doi : 10.1001/jamapsychiatry.2020.3285   IMPORTANCE : Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. OBJECTIVE : To investigate the effect of psilocybin [...]

Lire la suite

Futures prescriptions de cannabis à visée thérapeutique : mode d’emploi, Nicolas Authier, The Conversation, 23 juin 2019

Futures prescriptions de cannabis à visée thérapeutique : mode d’emploi Nicolas Authier The Conversation, 23 juin 2019   Depuis septembre 2018, l’Agence nationale de sécurité du médicament (ANSM) a mis en place un comité scientifique spécialisé temporaire (CSST) visant à réfléchir à la pertinence d’un accès en France à des préparations à base de cannabis à visée thérapeutique. La raison d’être de ce comité d’experts composé de médecins, de patients et de sociologues est de proposer une expérimentation visant à mieux soulager des patients qui souffrent, souvent depuis des années, sans trouver de solutions dans les thérapeutiques disponibles. Les travaux du CSST ne concernent [...]

Lire la suite

Qui pourra expérimenter le cannabis médical en France ?, Nicolas Authier, The Conversation, 8 septembre 2020

Qui pourra expérimenter le cannabis médical en France ? Nicolas Authier The Conversation, 8 septembre 2020   En octobre 2019, l’actuel ministre des Solidarités et de la Santé, Olivier Véran, alors député, présentait devant l’Assemblée nationale le texte qui allait devenir l’article 43 de la loi N°2019-1446 de financement de la Sécurité sociale pour 2020. Cet article donne notamment la possibilité à l’État d’autoriser, dans le cadre d’une expérimentation de politique publique, l’usage médical du cannabis sous la forme de produits répondant aux standards pharmaceutiques. Il s’agit de l’aboutissement de deux ans de réflexion menées en France sur la pertinence scientifique et les modalités d’accès [...]

Lire la suite